Display options
Cite
van Asperen JV, Fedorushkova DM, Robe PAJT, et al. Investigation of glial fibrillary acidic protein (GFAP) in body fluids as a potential biomarker for glioma: a systematic review and meta-analysis. Biomarkers. 2021;1-35doi: 10.1080/1354750X.2021.2006313.
van Asperen, J. V., Fedorushkova, D. M., Robe, P. A. J. T., & Hol, E. (2021). Investigation of glial fibrillary acidic protein (GFAP) in body fluids as a potential biomarker for glioma: a systematic review and meta-analysis. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, 1-35. https://doi.org/10.1080/1354750X.2021.2006313
van Asperen, Jessy Van, et al. "Investigation of glial fibrillary acidic protein (GFAP) in body fluids as a potential biomarker for glioma: a systematic review and meta-analysis." Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals vol. (2021): 1-35. doi: https://doi.org/10.1080/1354750X.2021.2006313
van Asperen JV, Fedorushkova DM, Robe PAJT, Hol E. Investigation of glial fibrillary acidic protein (GFAP) in body fluids as a potential biomarker for glioma: a systematic review and meta-analysis. Biomarkers. 2021 Nov 30;1-35. doi: 10.1080/1354750X.2021.2006313. Epub 2021 Nov 30. PMID: 34844498.
Copy Download .nbib Format: NLM
Share it on

Biomarkers. 2021 Nov 30;1-35. doi: 10.1080/1354750X.2021.2006313. Epub 2021 Nov 30.

Investigation of glial fibrillary acidic protein (GFAP) in body fluids as a potential biomarker for glioma: a systematic review and meta-analysis.

Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals

Jessy Van van Asperen, Daria M Fedorushkova, Pierre A J T Robe, Elly Hol

Affiliations

  1. Department of Translational Neurosciences, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands.
  2. Department of Neurology and Neurosurgery, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands.
  3. University Hospital Liege, Liege, Belgium.

PMID: 34844498 DOI: 10.1080/1354750X.2021.2006313

Abstract

INTRODUCTION: Liquid biopsies are promising diagnostic tools for glioma. In this quantitative systematic review, we investigate whether the detection of intermediate filaments (IF) in body fluids can be used as a tool for glioma diagnosis and prognosis.

MATERIALS AND METHODS: We included all studies in which IF-levels were determined in patients with glioma and healthy controls. Of the 28 identified eligible studies, 12 focused on levels of GFAP in serum (sGFAP) and were included for metadata analysis.

RESULTS: In all studies combined, 62.7% of all grade IV patients had detectable levels of sGFAP compared to 12.7% of healthy controls. sGFAP did not surpass the limit of detection in lower grade patients or healthy controls, but sGFAP was significantly elevated in grade IV glioma (0.12 ng/mL (0.06 - 0.18), P < 0.001) and showed an average median difference of 0.15 ng/mL (0.04 - 0.25, P < 0.01) compared to healthy controls. sGFAP levels were linked to tumour volume, but not to patient outcome.

CONCLUSION: The presence of sGFAP is indicative of grade IV glioma, but additional studies are necessary to fully determine the usefulness of GFAP in body fluids as a tool for grade IV glioma diagnosis and follow-up.

Keywords: GFAP; biomarker; blood serum; cytoskeleton; glioblastoma multiforme; intermediate filament

Publication Types